Roche Holding AG ADR Stock
Price
Target price
€45.28
€45.28
-1.080%
-0.4973
-1.080%
€46.97
26.05.26 / Tradegate
WKN: 891106 / Symbol: RHHBY / Name: Roche / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Roche Holding AG ADR is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Roche
sharewise wants to provide you with the best news and tools for Roche, so we directly link to the best financial data sources.
Financials
News
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
Key Points
- Interested in Climb Bio, Inc.? Here are five stocks we like better.
- Budoprutug, Climb Bio’s CD19-targeting antibody, is the company’s lead asset, with early data showing complete
Analog Devices Q2 Earnings Call Highlights
Key Points
- Interested in Analog Devices, Inc.? Here are five stocks we like better.
- Analog Devices posted record fiscal Q2 2026 results, with revenue of $3.62 billion, non-GAAP EPS of $3.09
Lineage Cell Therapeutics Q1 Earnings Call Highlights
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen
President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?
President Trump has made it a priority to address the U.S.'s high drug prices. His administration's Most-Favored-Nation (MFN) policy, centered on the idea that Americans shouldn't have to pay more
